BME:MED

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Medcomtech, S.A. distributes products in the areas of orthopedic surgery, traumatology, neurosurgery, and anesthesia worldwide.


Snowflake Analysis

Fair value with acceptable track record.

Share Price & News

How has Medcomtech's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MED has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0%

MED

3.9%

ES Healthcare

3.6%

ES Market


1 Year Return

-17.1%

MED

1.4%

ES Healthcare

-22.5%

ES Market

Return vs Industry: MED underperformed the Spanish Healthcare industry which returned 1.4% over the past year.

Return vs Market: MED exceeded the Spanish Market which returned -22.5% over the past year.


Shareholder returns

MEDIndustryMarket
7 Day0%3.9%3.6%
30 Day7.4%9.3%3.3%
90 Day-14.3%-6.0%-22.8%
1 Year-17.1%-17.1%2.1%1.4%-20.2%-22.5%
3 Year-76.6%-77.3%-17.5%-20.5%-27.1%-33.8%
5 Year-85.2%-85.7%-0.6%-6.1%-22.2%-34.4%

Price Volatility Vs. Market

How volatile is Medcomtech's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Medcomtech undervalued compared to its fair value and its price relative to the market?

2.93x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate MED's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate MED's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: MED is good value based on its PE Ratio (2.9x) compared to the Healthcare industry average (22x).

PE vs Market: MED is good value based on its PE Ratio (2.9x) compared to the Spanish market (14.8x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MED's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MED is good value based on its PB Ratio (1.3x) compared to the XE Healthcare industry average (1.8x).


Next Steps

Future Growth

How is Medcomtech forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

15.2%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Medcomtech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Medcomtech performed over the past 5 years?

-31.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MED has a high level of non-cash earnings.

Growing Profit Margin: MED became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: MED has become profitable over the past 5 years, growing earnings by -31.5% per year.

Accelerating Growth: MED has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: MED has become profitable in the last year, making it difficult to compare its past year earnings growth to the Healthcare industry (-2%).


Return on Equity

High ROE: MED's Return on Equity (43.4%) is considered outstanding.


Next Steps

Financial Health

How is Medcomtech's financial position?


Financial Position Analysis

Short Term Liabilities: MED's short term assets (€23.3M) exceed its short term liabilities (€16.6M).

Long Term Liabilities: MED's short term assets (€23.3M) exceed its long term liabilities (€6.9M).


Debt to Equity History and Analysis

Debt Level: MED's debt to equity ratio (93.9%) is considered high.

Reducing Debt: MED's debt to equity ratio has increased from 44.6% to 93.9% over the past 5 years.

Debt Coverage: MED's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: Insufficient data to determine if MED's interest payments on its debt are well covered by EBIT.


Balance Sheet


Next Steps

Dividend

What is Medcomtech's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MED's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MED's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MED's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MED's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: MED is not paying a notable dividend for the Spanish market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MED's dividend in 3 years as they are not forecast to pay a notable one for the Spanish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Juan Sagales Manas

no data

Tenure

Mr. Juan Sagales Manas serves as the Chairman of the Board, Chief Executive Officer and President at Medcomtech S.A. 


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Medcomtech, S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Medcomtech, S.A.
  • Ticker: MED
  • Exchange: BME
  • Founded: 2001
  • Industry: Health Care Distributors
  • Sector: Healthcare
  • Market Cap: €13.153m
  • Shares outstanding: 12.89m
  • Website: https://www.medcomtech.es

Number of Employees


Location

  • Medcomtech, S.A.
  • Edificio Brasil
  • Viladecans Business Park
  • Barcelona
  • Catalonia
  • 8840
  • Spain

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MEDBME (Bolsas y Mercados Espanoles)YesRegistered SharesESEURMar 2010

Biography

Medcomtech, S.A. distributes products in the areas of orthopedic surgery, traumatology, neurosurgery, and anesthesia worldwide. The company offers orthopedic surgery, trauma, and neurosurgery products for spine, hip-femur-knee, biologics, and upper and lower limbs, as well as biologics and cements. It also provides anesthesia products in the area of airway management. The company was founded in 2001 and is based in Barcelona, Spain. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/05/27 06:18
End of Day Share Price2020/05/26 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.